Citation
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs. // Blood Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2473952926004829?dgcid=rss_sd_all
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs. Blood Advances. https://www.sciencedirect.com/science/article/pii/S2473952926004829?dgcid=rss_sd_all
“Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs.” Blood Advances.
@article{article93354,
title = {Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs},
journal = {Blood Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2473952926004829?dgcid=rss_sd_all}
}